These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27932518)

  • 1. Epoetin-β induced pure red cell aplasia: an unintended consequence.
    Javaid MM; Khatri P; Subramanian S
    Postgrad Med J; 2017 Mar; 93(1097):168-169. PubMed ID: 27932518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pure red-cell aplasia and epoetin therapy.
    Bennett CL; Luminari S; Nissenson AR; Tallman MS; Klinge SA; McWilliams N; McKoy JM; Kim B; Lyons EA; Trifilio SM; Raisch DW; Evens AM; Kuzel TM; Schumock GT; Belknap SM; Locatelli F; Rossert J; Casadevall N
    N Engl J Med; 2004 Sep; 351(14):1403-8. PubMed ID: 15459301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study.
    Verhelst D; Rossert J; Casadevall N; Krüger A; Eckardt KU; Macdougall IC
    Lancet; 2004 May; 363(9423):1768-71. PubMed ID: 15172775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pure red cell aplasia induced by erythropoiesis-stimulating agents.
    Pollock C; Johnson DW; Hörl WH; Rossert J; Casadevall N; Schellekens H; Delage R; De Francisco A; Macdougall I; Thorpe R; Toffelmire E
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):193-9. PubMed ID: 18178785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure red-cell aplasia and recombinant erythropoietin.
    Gershon SK; Luksenburg H; Coté TR; Braun MM
    N Engl J Med; 2002 May; 346(20):1584-6; author reply 1584-6. PubMed ID: 12015400
    [No Abstract]   [Full Text] [Related]  

  • 6. Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis.
    Asari A; Gokal R
    J Am Soc Nephrol; 2004 Aug; 15(8):2204-7. PubMed ID: 15284306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery.
    Boven K; Knight J; Bader F; Rossert J; Eckardt KU; Casadevall N
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii33-40. PubMed ID: 15824129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].
    Opatrný K
    Cas Lek Cesk; 2003; 142(12):741-5. PubMed ID: 14746223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Possible complications of erythropoietin therapy in patients with chronic renal failure].
    Pljesa S
    Med Pregl; 2004; 57(5-6):254-7. PubMed ID: 15503795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetin-associated pure red cell aplasia: past, present, and future considerations.
    McKoy JM; Stonecash RE; Cournoyer D; Rossert J; Nissenson AR; Raisch DW; Casadevall N; Bennett CL
    Transfusion; 2008 Aug; 48(8):1754-62. PubMed ID: 18482185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pure red cell aplasia due to follow-on epoetin.
    Keithi-Reddy SR; Kandasamy S; Singh AK
    Kidney Int; 2008 Dec; 74(12):1617-22. PubMed ID: 18547998
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-epoetin-antibody-induced anemia in a child with chronic renal failure.
    Jöbsis JJ; Fijnvandraat K; Stapel SO; Bouts AH
    Pediatr Nephrol; 2010 May; 25(5):993-4. PubMed ID: 20165889
    [No Abstract]   [Full Text] [Related]  

  • 13. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
    Casadevall N; Nataf J; Viron B; Kolta A; Kiladjian JJ; Martin-Dupont P; Michaud P; Papo T; Ugo V; Teyssandier I; Varet B; Mayeux P
    N Engl J Med; 2002 Feb; 346(7):469-75. PubMed ID: 11844847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pure red cell aplasia associated with recombinant erythropoietin: a case report and brief review of the literature.
    Mohd Slim MA; Shaik R
    N Z Med J; 2013 Nov; 126(1386):106-10. PubMed ID: 24316999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.
    Cournoyer D; Toffelmire EB; Wells GA; Barber DL; Barrett BJ; Delage R; Forrest DL; Gagnon RF; Harvey EA; Laneuville P; Patterson BJ; Poon MC; Posen GA; Messner HA;
    J Am Soc Nephrol; 2004 Oct; 15(10):2728-34. PubMed ID: 15466278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
    Macdougall IC
    Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).
    Macdougall IC; Casadevall N; Locatelli F; Combe C; London GM; Di Paolo S; Kribben A; Fliser D; Messner H; McNeil J; Stevens P; Santoro A; De Francisco AL; Percheson P; Potamianou A; Foucher A; Fife D; Mérit V; Vercammen E;
    Nephrol Dial Transplant; 2015 Mar; 30(3):451-60. PubMed ID: 25239637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin-induced pure red cell aplasia successfully treated with androgens.
    Sánchez de la Nieta MD; Caparrós G; Rivera F
    J Nephrol; 2006; 19(2):220-1. PubMed ID: 16736425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pure red-cell aplasia secondary to antierythropoietin antibodies.
    Guest SS; Levitt L
    N Engl J Med; 2003 Dec; 349(26):2572-3. PubMed ID: 14695426
    [No Abstract]   [Full Text] [Related]  

  • 20. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure.
    Lim LC
    Hematology; 2005 Jun; 10(3):255-9. PubMed ID: 16019474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.